Frost & Sullivan

JUNE 26, 2024

Life science companies are intensifying omics-based research and forming strategic partnerships to develop effective pharmacological and digital therapies. The convergence of biopharma, digital therapeutics, medical devices, and health technology is enhancing patient care, improving outcomes, and reducing costs.

Biopharma 40

Biopharma Life science Strategic partnership Ecosystems 40

Frost & Sullivan

MAY 9, 2025

The Expanding Role of Clinical Contract Peripheral Services As the pharmaceutical and biopharma industries recalibrate after the COVID-19 pandemic, clinical trial outsourcing has surged, creating significant opportunities for contract research organizations (CROs). The global CRO industry, valued at $66.39 billion by 2030.

Mergers and acquisition activities 52

Mergers and acquisition activities Biopharma Biotechnology Biotech 52

Frost & Sullivan

MARCH 16, 2025

The Proteomics Ecosystem: Whos Driving Innovation? The proteomics ecosystem is highly consolidated at the top, with a few major players dominating the industry while smaller companies emerge with innovative solutions. Strategic partnerships with bioinformatics firms and academic institutions will drive next-gen proteomics innovations.

Biopharma 52

Biopharma Strategic alliances Strategic partnership Ecosystems 52